ClinicalTrials.gov
public full text
Public Domain
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.#865819
- Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy#916555
- Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer#1005329
- Endocrine Therapy Base on 21-gene RS#968756
- A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors#842505
Record · ID 875579
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive